Comparative Pharmacology
Head-to-head clinical analysis: ENLON versus NEOSTIGMINE METHYLSULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENLON versus NEOSTIGMINE METHYLSULFATE.
ENLON vs NEOSTIGMINE METHYLSULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
None Documented
None Documented
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor